Overview
Complex Psoriasis Patients and Challenging Areas to Treat
Clinical Decision Point Challenges
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This case-based activity addresses complex scenarios in psoriasis, including challenging areas, severe disease, and other complexities. Clinical decision points and video-based discussion from a dermatologist and nurse practitioner throughout the activity address the burden of psoriasis, its impact on quality-of-life, and available approaches to challenging areas and severe disease.
This activity is intended for dermatologists and other healthcare providers who care for patients with psoriasis.
Areas of plaque psoriasis that are particularly challenging to treat are more common than previously thought, and these areas may not respond as well to traditional treatment approaches. Moreover, they are associated with lower patient quality of life. Clinicians can provide valuable patient-centered care for these psoriasis manifestations by facilitating discussions about treatment goals and formulating individualized approaches using one or more agents from the diverse therapeutic armamentarium for psoriasis.
Upon completion of this activity, participants will be able to:
• Review clinical strategies for recognition of psoriasis in difficult-to-treat areas
• Summarize key clinical challenges and unmet needs in the management of difficult-to-treat psoriasis
• Assess the rationale and current evidence for treatment of difficult-to-treat psoriasis, including biologic agents
• Review clinical strategies for recognition of psoriasis in difficult-to-treat areas
• Summarize key clinical challenges and unmet needs in the management of difficult-to-treat psoriasis
• Assess the rationale and current evidence for treatment of difficult-to-treat psoriasis, including biologic agents
Sponsored by Purdue University College of Pharmacy and the Academy for Continued Healthcare Learning.
Supported by educational grants from Celgene Corporation and Novartis Pharmaceuticals Corporation.
Anthony Fernandez, MD, PhD
Director of Medical Dermatology
W.D. Steck Chair of Clinical Dermatology
Departments of Dermatology and Pathology
Dermatology and Plastic Surgery Institute
Cleveland Clinic
Cleveland, OH
Director of Medical Dermatology
W.D. Steck Chair of Clinical Dermatology
Departments of Dermatology and Pathology
Dermatology and Plastic Surgery Institute
Cleveland Clinic
Cleveland, OH
Lakshi M. Aldredge, MSN, ANP-BC, DCNP
Dermatology Nurse Practitioner
VA Portland Healthcare System
Portland, OR
Purdue University College of Pharmacy and the Academy for Continued Healthcare Learning (ACHL) require that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Anthony Fernandez, MD, PhD
Grants/Research Support: Mallinckrodt, Novartis
Principle Investigator for a Drug Study: Mallinckrodt, Pfizer, Corbus
Consultant: AbbVie, Novartis, Mallinckrodt, UCB
Speakers Bureau: AbbVie, Novartis, Mallinckrodt
Honoraria: AbbVie, Novartis, Mallinckrodt, UCB
Lakshi M. Aldredge, MSN, ANP-BC, DCNP
Speakers Bureau, Advisory Board, Honoraria: AbbVie, Lilly, Sanofi Genzyme, Sun Pharma, Regeneron
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
All additional planning committee members, ACHL, and Purdue University College of Pharmacy have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporters. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL and Purdue University require their speakers to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, please contact Katlyn Cooper at kcooper@achlcme.org.
Purdue University College of Pharmacy is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Purdue University College of Pharmacy designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Completion of this activity including the pre, post, and follow-up assessments qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.